Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2005

View Archived Issues

DA-8159 prevents erectile dysfunction associated with hypercholesterolemia

Preclinical and phase II data on the analgesic effects of ajulemic acid

Vildagliptin effectively improves beta cell function and post-meal insulin sensitivity

Duloxetine improves functional outcomes in the treatment of DNP

Clinical evaluation of ERTs for Fabry's disease / News in Context

HyperAcute Lung Cancer Vaccine safe and feasible in NSCLC

ACV-1 enters phase I testing

Enrollment begins in SPIRIT III study of Xience V stent

Orphan Medical stockholders approve acquisition by Jazz Pharmaceuticals

CAT-354 well tolerated in mild asthmatic patients

Civacir receives European orphan medicinal product designation

PPD licenses GGTase inhibitor compounds to Duke University

Melanotan studied in new Australian phase IIb study

Worldwide launch of Cumulase

SciClone files IND for SCV-07

Dynavax initiates phase III trial for HBV vaccine

New phase II study evaluates talabostat for metastatic pancreatic cancer

MN-029 enters second phase I study for solid tumors

Recent patents describe novel agents for cardiovascular diseases

New compounds for possible use in psychosis, depression, schizophrenia, etc.

Gamma-secretase inhibitors for Alzheimer's reported by Pfizer

Preclinical studies characterize the activity of oleoyl estrone

Positive opinion for Tarceva in Europe

Once-monthly Bonviva receives recommendation from European CHMP

Keppra approved for childhood epilepsy

Vasovist receives positive opinion in Europe

Zonegran launched in U.K., Germany

Azilect launched in U.K.

BiDil approved for treatment of heart failure in black patients

Preliminary results from phase I trial of recombinant AAV alpha1-antitrypsin vector gene therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...